Literature DB >> 27847923

Stages of the clinical course of schizophrenia - staging concept.

Paweł Wójciak1, Agnieszka Remlinger-Molenda1, Janusz Rybakowski1.   

Abstract

Clinical staging is a tool useful in medical sciences. It assumes the presence of three key elements. Firstly, pathologic indices are progressing in subsequent stages. Secondly, the patients in the individual stages present similar pathological changes. Thirdly, treatment should be most effective in the earlier stages. Such model is particularly well established in the treatment of malignancies. Staging is useful here to define prognosis, to evaluate the results of treatment, facilitate the exchange and comparison of information among treatment centres. There is much data describing a similar model for mental illnesses including schizophrenia. There are two theories supporting the staging model for schizophrenia: the neurodevelopmental hypothesis and allostatic load concept. Both theories make a theoretical premise for creating the staging model for schizophrenia. We can describe at least three stages in the development of a schizophrenic illness: the prodrome, the first episode and chronic phase. Each stage is reflected by anatomical and functional changes in the brain. Therefore, a clinical staging model can describe a development of schizophrenia over time, to help selecting adequate treatments that are particularly relevant to a given stage and to show the relations between known biological markers and psychosocial risk factors and the stage of the illness.

Entities:  

Keywords:  phases; schizophrenia; staging

Mesh:

Year:  2016        PMID: 27847923     DOI: 10.12740/PP/58723

Source DB:  PubMed          Journal:  Psychiatr Pol        ISSN: 0033-2674            Impact factor:   1.657


  4 in total

1.  SKINREMS-A New Method for Assessment of the Niacin Skin Flush Test Response in Schizophrenia.

Authors:  Hanna Karakula-Juchnowicz; Joanna Rog; Piotr Wolszczak; Kamil Jonak; Ewa Stelmach; Paweł Krukow
Journal:  J Clin Med       Date:  2020-06-13       Impact factor: 4.241

2.  Association between mitochondrial DNA and cognitive impairment in schizophrenia: study protocol for a Mexican population.

Authors:  Dulce Dajheanne García-de la Cruz; Isela Esther Juárez-Rojop; Carlos Alfonso Tovilla-Zárate; José Jaime Martínez-Magaña; Alma Delia Genis-Mendoza; Humberto Nicolini; Thelma Beatriz González-Castro; Crystell Guadalupe Guzmán-Priego; Nancy Adanelly López-Martínez; Javier Antonio Hernández-Cisneros; Francisco Caballero-Prado
Journal:  Neuropsychiatr Dis Treat       Date:  2019-06-28       Impact factor: 2.570

3.  Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study.

Authors:  Konstantinos N Fountoulakis; Elena Dragioti; Antonis T Theofilidis; Tobias Wikilund; Xenofon Atmatzidis; Ioannis Nimatoudis; Erik Thys; Martien Wampers; Luchezar Hranov; Trayana Hristova; Daniil Aptalidis; Roumen Milev; Felicia Iftene; Filip Spaniel; Pavel Knytl; Petra Furstova; Tiina From; Henry Karlsson; Maija Walta; Raimo K R Salokangas; Jean-Michel Azorin; Justine Bouniard; Julie Montant; Georg Juckel; Ida S Haussleiter; Athanasios Douzenis; Ioannis Michopoulos; Panagiotis Ferentinos; Nikolaos Smyrnis; Leonidas Mantonakis; Zsófia Nemes; Xenia Gonda; Dora Vajda; Anita Juhasz; Amresh Shrivastava; John Waddington; Maurizio Pompili; Anna Comparelli; Valentina Corigliano; Elmars Rancans; Alvydas Navickas; Jan Hilbig; Laurynas Bukelskis; Lidija Injac Stevovic; Sanja Vodopic; Oluyomi Esan; Oluremi Oladele; Christopher Osunbote; Janusz Κ Rybakowski; Pawel Wojciak; Klaudia Domowicz; Maria Luisa Figueira; Ludgero Linhares; Joana Crawford; Anca-Livia Panfil; Daria Smirnova; Olga Izmailova; Dusica Lecic-Tosevski; Henk Temmingh; Fleur Howells; Julio Bobes; Maria Paz Garcia-Portilla; Leticia García-Alvarez; Gamze Erzin; Hasan Karadağ; Avinash De Sousa; Anuja Bendre; Cyril Hoschl; Cristina Bredicean; Ion Papava; Olivera Vukovic; Bojana Pejuskovic; Vincent Russell; Loukas Athanasiadis; Anastasia Konsta; Dan Stein; Michael Berk; Olivia Dean; Rajiv Tandon; Siegfried Kasper; Marc De Hert
Journal:  Int J Neuropsychopharmacol       Date:  2019-11-01       Impact factor: 5.176

4.  Plasma β-III tubulin, neurofilament light chain and glial fibrillary acidic protein are associated with neurodegeneration and progression in schizophrenia.

Authors:  Daniela Rodrigues-Amorim; Tania Rivera-Baltanás; María Del Carmen Vallejo-Curto; Cynthia Rodriguez-Jamardo; Elena de Las Heras; Carolina Barreiro-Villar; María Blanco-Formoso; Patricia Fernández-Palleiro; María Álvarez-Ariza; Marta López; Alejandro García-Caballero; José Manuel Olivares; Carlos Spuch
Journal:  Sci Rep       Date:  2020-08-31       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.